WO2018069851A3 - C-met antibody drug conjugate - Google Patents

C-met antibody drug conjugate Download PDF

Info

Publication number
WO2018069851A3
WO2018069851A3 PCT/IB2017/056295 IB2017056295W WO2018069851A3 WO 2018069851 A3 WO2018069851 A3 WO 2018069851A3 IB 2017056295 W IB2017056295 W IB 2017056295W WO 2018069851 A3 WO2018069851 A3 WO 2018069851A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
drug conjugate
antibody drug
drug
met antibody
Prior art date
Application number
PCT/IB2017/056295
Other languages
French (fr)
Other versions
WO2018069851A2 (en
Inventor
Tong Zhu
Gang Chen
Alisher Khasanov
Original Assignee
Sorrento Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sorrento Therapeutics, Inc. filed Critical Sorrento Therapeutics, Inc.
Publication of WO2018069851A2 publication Critical patent/WO2018069851A2/en
Publication of WO2018069851A3 publication Critical patent/WO2018069851A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Described are antibody drug conjugates (ADCs) having an IgG antibody (A) that binds to a c-Met target, conjugated through a conjugation component at both Cys sites in the hinge region of the IgG antibody and to disulfide bonds linking heavy and light chains of the IgG class human antibody, to a drug (D). More specifically, the present disclosure relates to the drug component (D) of the ADC.
PCT/IB2017/056295 2016-10-11 2017-10-11 C-met antibody drug conjugate WO2018069851A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662406746P 2016-10-11 2016-10-11
US62/406,746 2016-10-11

Publications (2)

Publication Number Publication Date
WO2018069851A2 WO2018069851A2 (en) 2018-04-19
WO2018069851A3 true WO2018069851A3 (en) 2018-06-07

Family

ID=61906238

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2017/056295 WO2018069851A2 (en) 2016-10-11 2017-10-11 C-met antibody drug conjugate

Country Status (1)

Country Link
WO (1) WO2018069851A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI782930B (en) 2016-11-16 2022-11-11 美商再生元醫藥公司 Anti-met antibodies, bispecific antigen binding molecules that bind met, and methods of use thereof
AU2018211561B2 (en) 2017-01-24 2020-04-30 Pfizer Inc. Calicheamicin derivatives and antibody drug conjugates thereof
CN114340684A (en) 2019-09-16 2022-04-12 瑞泽恩制药公司 Radiolabeled MET binding proteins for immunopet imaging
CN117659203A (en) * 2023-12-06 2024-03-08 科弈(浙江)药业科技有限公司 anti-MET/EGFR bispecific antibody and drug conjugate thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5714586A (en) * 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
WO2016094455A1 (en) * 2014-12-08 2016-06-16 Sorrento Therapeutics, Inc. C-met antibody drug conjugate
WO2016123412A1 (en) * 2015-01-28 2016-08-04 Sorrento Therapeutics, Inc. Antibody drug conjugates

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5714586A (en) * 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
WO2016094455A1 (en) * 2014-12-08 2016-06-16 Sorrento Therapeutics, Inc. C-met antibody drug conjugate
WO2016123412A1 (en) * 2015-01-28 2016-08-04 Sorrento Therapeutics, Inc. Antibody drug conjugates

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HAMANN ET AL.: "An Anti-MUC1 Antibody-Calicheamicin Conjugate for Treatment of Solid Tumors. Choice of Linker and Overcoming Drug Resistance", BIOCONJUGATE CHEMISTRY, vol. 16, no. 2, 1 March 2005 (2005-03-01), pages 346 - 353, XP055272665 *
SENTER: "Potent antibody drug conjugates for cancer therapy", CURRENT OPINION IN CHEMICAL BIOLOGY, vol. 13, no. 3, 4 May 2009 (2009-05-04), pages 235 - 244, XP026285196 *

Also Published As

Publication number Publication date
WO2018069851A2 (en) 2018-04-19

Similar Documents

Publication Publication Date Title
WO2018069851A3 (en) C-met antibody drug conjugate
HRP20210170T1 (en) Anti-b7-h3 antibodies and antibody drug conjugates
WO2017031034A3 (en) Covalent linkers in antibody-drug conjugates and methods of making and using the same
WO2017062271A3 (en) Antibody drug conjugate for anti-inflammatory applications
EP3783025A4 (en) Targeted cd73 antibody and antibody-drug conjugate, and preparation method therefor and uses thereof
MX2022014125A (en) Antibodies and conjugates thereof.
PH12018500693A1 (en) Pyrrolobenzodiazepine antibody drug conjugates and methods of use
WO2015057876A8 (en) Drug-conjugates with a targeting molecule and two different drugs
EP3626825A4 (en) Anti-cdh6 antibody and anti-cdh6 antibody-drug conjugate
MX2019010804A (en) Benzazepine compounds, conjugates, and uses thereof.
MX2020006409A (en) Ror1-specific antigen binding molecules.
CO2020015084A2 (en) Anti-msr1 antibodies and methods of using them
WO2012064733A3 (en) Antibody scaffold for homogenous conjugation
EP3572428A4 (en) Anti-gpr20 antibody and anti-gpr20 antibody-drug conjugate
EP3411074A4 (en) Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof
EP3958910A4 (en) Anti-cd45 antibody drug conjugates and uses thereof
NZ701040A (en) Covalently linked antigen-antibody conjugates
EP3695852A4 (en) Anti-mesothelin antibody and antibody-drug conjugate thereof
WO2007044616A3 (en) Optimized anti-cd30 antibodies
IL214983A0 (en) Antibody drug conjugated that bind monomethyl auristatin e (mmae), compositions comprisimg the same and uses thereof
EP3580239A4 (en) Anti-ilt3 antibodies and antibody drug conjugates
EP4025257A4 (en) Antibody-drug conjugate comprising antibody against human ror1, and use for the same
MY194477A (en) Pyrrolobenzodiazepine conjugates
WO2016094455A8 (en) C-met antibody drug conjugate
WO2018119196A8 (en) Immunoconjugates targeting adam9 and methods of use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17860992

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17860992

Country of ref document: EP

Kind code of ref document: A2